GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
131.70
-0.93 (-0.70%)
Sep 29, 2026, 10:51 AM EDT - Market open
GRAIL Revenue
GRAIL had revenue of $44.69M in the quarter ending June 30, 2026, with 25.72% growth. This brings the company's revenue in the last twelve months to $165.26M, up 23.07% year-over-year. In the year 2025, GRAIL had annual revenue of $147.17M with 17.18% growth.
Revenue (ttm)
$165.26M
Revenue Growth
+23.07%
P/S Ratio
35.85
Revenue / Employee
$181,608
Employees
910
Market Cap
5.88B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 147.17M | 21.58M | 17.18% |
| Dec 31, 2024 | 125.60M | 32.49M | 34.90% |
| Dec 31, 2023 | 93.11M | 37.56M | 67.61% |
| Jan 1, 2023 | 55.55M | 40.94M | 280.17% |
| Jan 2, 2022 | 14.61M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ICON Public Limited Company | 8.29B |
| Charles River Laboratories International | 4.00B |
| RadNet | 2.27B |
| Qiagen | 2.10B |
| Sotera Health Company | 1.22B |
| NeoGenomics | 766.30M |
| Veracyte | 561.90M |
| CareDx | 458.09M |
GRAL News
- 1 day ago - Grail price target raised to $150 from $80 at Canaccord - TheFly
- 4 days ago - Grail price target raised to $100 from $65 at Mizuho - TheFly
- 5 days ago - Grail panel votes ‘closer than we expected,’ says BTIG - TheFly
- 5 days ago - AdCom meeting for Grail’s Galleri test better than expected, says Canaccord - TheFly
- 5 days ago - TD ups Grail approval probability to 95% after panel vote - TheFly
- 5 days ago - Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval - WSJ
- 5 days ago - Grail says FDA panel recommendations ‘reaffirm high evidence bar’ for Galleri - TheFly
- 5 days ago - FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test - PRNewsWire